Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

[This corrects the article DOI: 10.3389/fimmu.2021.709861.].

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2022-01, Vol.12, p.815812-815812
Main Authors: Moreira, Thais G, Matos, Kimble T F, De Paula, Giovana S, Santana, Thais M M, Da Mata, Raquel G, Pansera, Fernando C, Cortina, Andre S, Spinola, Marcelle G, Baecher-Allan, Clare M, Keppeke, Gerson D, Jacob, Jules, Palejwala, Vaseem, Chen, Karen, Izzy, Saef, Healey, Brian C, Rezende, Rafael M, Dedivitis, Rogerio A, Shailubhai, Kunwar, Weiner, Howard L
Format: Article
Language:English
Subjects:
anti-CD3
COVID-19
foralumab
immune responses
Immunology
SARS-CoV-2
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[This corrects the article DOI: 10.3389/fimmu.2021.709861.].
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.815812